Brefonalol is a beta-adrenergic antagonist that reduces heart frequency and blood pressure and dilates blood vessels. It has been studied in around 1990,[1] but is not known to be marketed as of 2021.

References

  1. ^ Halabi, A; Endell, W; Halabi, I; Kirch, W (1990). "Hemodynamic effects of brefanolol and propranolol assessed by noninvasive methods in patients with arterial hypertension". Journal of Cardiovascular Pharmacology. 16 (1): 81–6. doi:10.1097/00005344-199007000-00011. PMID 1696669. S2CID 41692901.